Pharmacological targeting of lysine acetyltransferases in human disease: a progress report

Drug Discovery Today

Volumn 12, Issue 1-2, 2007, Pages 88-99

  Heery, David M ^a   Fischer, Peter M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLHISTAMINE; AMINO ACID ACETYLTRANSFERASE; ANACARDIC ACID; CORTICOSTEROID; CURCUMIN; ENZYME INHIBITOR; ERI 7; GARCINOL; HORMONE RECEPTOR BLOCKING AGENT; INDOLYLBUTENONE; ISOTHIAZOLONE; LYSINE ACETYLTRANSFERASE; LYSINE ACETYLTRANSFERASE INHIBITOR; MS 7972; NAPHTHOQUINOLINONE; PHENYLPROPANEDIAMINE; TAMOXIFEN; TRIAZOLOPYRIMIDINE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; BRONCHUS HYPERREACTIVITY; CANCER; CANCER CELL; CHROMOSOME TRANSLOCATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTAL STRUCTURE; DRUG ACETYLATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCRINE DISEASE; ENZYME ACTIVE SITE; ENZYME MECHANISM; ENZYME STRUCTURE; EPIGENETICS; HEMATOPOIETIC CELL; HUMAN; HUMAN GENOME; LEUKEMOGENESIS; METABOLIC DISORDER; ONCOLOGY; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ALIGNMENT; STRUCTURE ANALYSIS;

ACETYLTRANSFERASES; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LYSINE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS;

EID: 33845746277     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.11.012     Document Type: Review

References (107)

1. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32 (2004) 959-976
2. Swaminathan V., et al. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol. Cell. Biol. 25 (2005) 7534-7545
3. Glozak M.A., et al. Acetylation and deacetylation of non-histone proteins. Gene 363 (2005) 15-23
4. Sterner D.E., and Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64 (2000) 435-459
5. Marmorstein R. Biochemical and structural characterization of recombinant histone acetyltransferase proteins. Methods Enzymol. 376 (2004) 106-119
6. Thompson P.R., et al. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 11 (2004) 308-315
7. Yang X.J. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays 26 (2004) 1076-1087
8. Heery D.M., et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997) 733-736
9. Xu J., and Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17 (2003) 1681-1692
10. Darimont B.D., et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12 (1998) 3343-3356
11. Koumenis C., and Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell. Biol. 17 (1997) 7306-7316
12. Phillips A.C., and Vousden K.H. Acetyltransferases and tumour suppression. Breast Cancer Res. 2 (2000) 244-246
13. Kung A.L., et al. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev. 14 (2000) 272-277
14. Seligson D.B., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
15. Di Croce L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum. Mol. Genet. 14 (2005) 77-84
16. Sobulo O.M., et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8732-8737
17. Daser A., and Rabbitts T.H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 18 (2004) 965-974
18. Troke P.J., et al. MOZ fusion proteins in acute myeloid leukaemia. Biochem. Soc. Symp. 73 (2005) 23-39
19. Kindle K.B., et al. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol. Cell. Biol. 25 (2005) 988-1002
20. Liao L., et al. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J. Steroid Biochem. Mol. Biol. 83 (2002) 3-14
21. Kershah S.M., et al. Expression of estrogen receptor coregulators in normal and malignant human endometrium. Gynecol. Oncol. 92 (2004) 304-313
22. Clarke R., et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53 (2001) 25-71
23. Waters L., et al. Structural diversity in p160/CREB-binding protein coactivator complexes. J. Biol. Chem. 281 (2006) 14787-14795
24. Fu M., et al. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol. 68 (2004) 1199-1208
25. Barnes P.J. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161 (2000) 342-344
26. Ito K., et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352 (2005) 1967-1976
27. Barnes P.J., et al. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respir. J. 25 (2005) 552-563
28. Cosio B.G., et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J. Exp. Med. 200 (2004) 689-695
29. Barnes P.J. Corticosteroids: The drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
30. Lusic M., et al. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 22 (2003) 6550-6561
31. Bannwarth S., and Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr. HIV Res. 3 (2005) 61-71
32. Van Lint C., et al. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15 (1996) 1112-1120
33. Kaehlcke K., et al. Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation. Mol. Cell 12 (2003) 167-176
34. Dorr A., et al. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J. 21 (2002) 2715-2723
35. Quivy V., et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J. Virol. 76 (2002) 11091-11103
36. Demonte D., et al. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem. Pharmacol. 68 (2004) 1231-1238
37. Balasubramanyam K., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279 (2004) 51163-51171
38. Varier R.A., and Kundu T.K. Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy. Curr. Pharm. Des. 12 (2006) 1975-1993
39. Mosley A.L., and Ozcan S. Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J. Biol. Chem. 278 (2003) 19660-19666
40. Chakrabarti S.K., et al. Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells. J. Biol. Chem. 278 (2003) 23617-23623
41. Gray S.G., and De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 21 (2005) 416-433
42. Yamauchi T., et al. Increased insulin sensitivity despite lipodystrophy in CREBbp heterozygous mice. Nat. Genet. 30 (2002) 221-226
43. Tsuchida A., et al. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin. J. Pharmacol. Sci. 97 (2005) 164-170
44. Zheng Y., et al. Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol. 376 (2004) 188-199
45. Cebrat M., et al. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 11 (2003) 3307-3313
46. Zheng Y., et al. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J. Am. Chem. Soc. 127 (2005) 17182-17183
47. Balasubramanyam K., et al. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278 (2003) 19134-19140
48. Varier R.A., et al. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem. Pharmacol. 68 (2004) 1215-1220
49. Maheshwari R.K., et al. Multiple biological activities of curcumin: a short review. Life Sci. 78 (2006) 2081-2087
50. Marcu M.G., et al. Curcumin is an inhibitor of p300 histone acetyltransferase. Med. Chem. 2 (2006) 169-174
51. Thompson P.R., et al. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 276 (2001) 33721-33729
52. Bordoli L., et al. Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity. Nucleic Acids Res. 29 (2001) 4462-4471
53. Kang J., et al. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 69 (2005) 1205-1213
54. Tourkina E., et al. Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am. J. Respir. Cell Mol. Biol. 31 (2004) 28-35
55. Shao Z.M., et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer 98 (2002) 234-240
56. Mishra S., et al. Differential apoptotic and redox regulatory activities of curcumin and its derivatives. Free Radic. Biol. Med. 38 (2005) 1353-1360
57. Weber W.M., et al. Anti-oxidant activities of curcumin and related enones. Bioorg. Med. Chem. 13 (2005) 3811-3820
58. Sharma R.A., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. 10 (2004) 6847-6854
59. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
60. Pan M.H., et al. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 27 (1999) 486-494
61. Balasubramanyam K., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279 (2004) 33716-33726
62. Pan M.-H., et al. Induction of apoptosis by garcinol and curcumin through cytochrome C release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem. 49 (2001) 1464-1474
63. Baggett S., et al. Bioactive benzophenones from Garcinia xanthochymus fruits. J. Nat. Prod. 68 (2005) 354-360
64. Moore L.B., et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7500-7502
65. Wentworth J.M., et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol. 166 (2000) R11-R16
66. Hostanska K., et al. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur. J. Pharm. Biopharm. 56 (2003) 121-132
67. Schempp C.M., et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 21 (2002) 1242-1250
68. Gartner M., et al. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. ChemBioChem 6 (2005) 171-177
69. Biel M., et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew. Chem. Int. Ed. Engl. 43 (2004) 3974-3976
70. Stimson L., et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 4 (2005) 1521-1532
71. Galande A.K., et al. Potent inhibitors of LXXLL-based protein-protein interactions. ChemBioChem 6 (2005) 1991-1998
72. Rodriguez A.L., et al. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47 (2004) 600-611
73. Shao D., et al. Identification of novel estrogen receptor alpha antagonists. J. Steroid Biochem. Mol. Biol. 88 (2004) 351-360
74. Arnold L.A., et al. Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J. Biol. Chem. 280 (2005) 43048-43055
75. Heery D.M., et al. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 276 (2001) 6695-6702
76. Coulthard V.H., et al. An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J. Biol. Chem. 278 (2003) 10942-10951
77. Zeng L., and Zhou M.M. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 513 (2002) 124-128
78. Owen D.J., et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 19 (2000) 6141-6149
79. Dhalluin C., et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399 (1999) 491-496
80. Mujtaba S., et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 13 (2004) 251-263
81. Jacobson R.H., et al. Structure and function of a human TAFII250 double bromodomain module. Science 288 (2000) 1422-1425
82. Mujtaba S., et al. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol. Cell 9 (2002) 575-586
83. Hudson B.P., et al. Solution structure and acetyl-lysine binding activity of the GCN5 bromodomain. J. Mol. Biol. 304 (2000) 355-370
84. Sachchidanand R.-S.L., et al. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 13 (2006) 81-90
85. Zeng L., et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127 (2005) 2376-2377
86. Yoo C.B., and Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5 (2006) 37-50
87. Majmudar C.Y., and Mapp A.K. Chemical approaches to transcriptional regulation. Curr. Opin. Chem. Biol. 9 (2005) 467-474
88. Kleff S., et al. Identification of a gene encoding a yeast histone H4 acetyltransferase. J. Biol. Chem. 270 (1995) 24674-24677
89. Utley R.T., and Cote J. The MYST family of histone acetyltransferases. Curr. Top. Microbiol. Immunol. 274 (2003) 203-236
90. Brownell J.E., et al. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84 (1996) 843-851
91. Yang X.J., et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382 (1996) 319-324
92. Ogryzko V.V., et al. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 (1996) 953-959
93. Bannister A.J., and Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 384 (1996) 641-643
94. Spencer T.E., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389 (1997) 194-198
95. Chen H., et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90 (1997) 569-580
96. Hsieh Y.J., et al. The TFIIIC90 subunit of TFIIIC interacts with multiple components of the RNA polymerase III machinery and contains a histone-specific acetyltransferase activity. Mol. Cell. Biol. 19 (1999) 7697-7704
97. Kawasaki H., et al. ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405 (2000) 195-200
98. Raval A., et al. Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. Mol. Cell 7 (2001) 105-115
99. Mizzen C.A., et al. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87 (1996) 1261-1270
100. Lahn B.T., et al. Previously uncharacterized histone acetyltransferases implicated in mammalian spermatogenesis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8707-8712
101. Choi C.H., et al. Transcription factor IIB acetylates itself to regulate transcription. Nature 424 (2003) 965-969
102. Takei Y., et al. MCM3AP, a novel acetyltransferase that acetylates replication protein MCM3. EMBO Rep. 2 (2001) 119-123
103. Ivanov D., et al. Eco1 is a novel acetyltransferase that can acetylate proteins involved in cohesion. Curr. Biol. 12 (2002) 323-328
104. Jeong J.W., et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111 (2002) 709-720
105. Doi M., et al. Circadian regulator CLOCK is a histone acetyltransferase. Cell 125 (2006) 497-508
106. Poux A.N., et al. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14065-14070
107. Toleman C., et al. Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. J. Biol. Chem. 279 (2004) 53665-53673